Ignite Creation Date:
2024-05-06 @ 7:40 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06094556
Status:
RECRUITING
Last Update Posted:
2024-02-20
First Post:
2023-10-16
Brief Title:
An Open Phase I Clinical Trial of SHR-1826 for Injection in Patients With Advanced Solid Tumors
Sponsor:
Suzhou Suncadia Biopharmaceuticals Co Ltd
Organization:
Suzhou Suncadia Biopharmaceuticals Co Ltd
Study Overview
Official Title:
A Multicenter Open Phase I Clinical Study of Safety Tolerability Pharmacokinetics and Efficacy of SHR-1826 for Injection in Patients With Advanced Solid Tumors
Status:
RECRUITING
Status Verified Date:
2024-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is an open multi-center dose-escalationdose-expansionefficacy expansion phase I clinical study to evaluate the tolerability safety PK and immunogenicity of SHR-1826 in patients with advanced malignant solid tumors and to preliminatively observe its antitumor efficacy The whole study was divided into three stages dose increment dose extension and therapeutic effect extension
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None